Breaking News, Financial News

Johnson & Johnson 4Q Revenues Slip 4%

Growth for DARZALEX, STELARA, ERLEADA, TREMFYA and INVEGA SUSTENNA offset by declines for REMICADE, IMBRUVICA, ZYTIGA, and COVID-19 vaccines.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Johnson & Johnson 4Q Revenues: $23.7 billion (-4%) 4Q Earnings: $3.5 billion (-26%) YTD Revenues: $94.9 billion (+1%) YTD Earnings: $17.9 billion (-14%) Comments: Pharmaceutical sales were $13.2 billion in the quarter, down 7% and $52.6 billion for the year, up 2%. Pharmaceutical sales growth for the year was driven by DARZALEX (up 32% to $8.0 billion), a biologic for the treatment of multiple myeloma, STELARA ( up 7% to $9.7 billion), a biologic for the treatment of a number of immune-...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters